Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, July 2, 2015

CHIMES-E study: NeuroAiD provides long-term benefits to patients after ischemic stroke

Since the source is Moleac I really don't trust anything in here. Can't tell what cherry-picking of patients occurred or what other therapies were given so you can't tell which intervention actually helped. Or was this all just spontaneous recovery?
 

CHIMES-E study: NeuroAiD provides long-term benefits to patients after ischemic stroke

The odds of functional independence defined as a modified Rankin Score (mRS) </= 1 were significantly increased at 6 months and persisted up to 18 months after stroke in the NeuroAiD™ group.
Moleac is pleased to announce the release of the CHIMES-E study results published online in the journal Cerebrovascular Diseases. It provides convincing data on NeuroAiD which confirm its persistent long-term benefits on patients' recovery after an ischemic stroke. The CHIMES-E study results were first announced by Prof. Christopher Chen (CHIMES-E co-principal investigator) during the European Stroke Organization Conference (ESOC 2015) in Glasgow, April 17-19, as part of the Scientific Program during the Clinical Trial session.
The CHIMES-E study is a planned, international and multicenter study performed in a blinded and placebo-controlled manner. It has included 880 patients from the CHIMES study who have suffered an ischemic stroke of intermediate severity within 72 hours, treated with NeuroAiD™ or placebo for 3 months after the initial stroke. The main purpose of this study was to evaluate the effects of an initial 3-month course with NeuroAiD™ on long-term outcomes for up to 2 years.
This study has showed that NeuroAiD™ increases significantly the odds of achieving functional independence at 6 months which persisted up to 18 months after stroke, as measured by the mRS. All these results were consistent at various time points and seen on 2 indices, i.e. mRS and BI. It also provided further long-term safety data on NeuroAiD™, even when combined with other stroke treatments. "These persistent benefits seen up to 18 months are a clinical confirmation of the previously established neurorestorative properties (i.e. neuroplasticity and neurogenesis) of NeuroAiD™, and suggest that it may be beneficial to extend NeuroAiD™ treatment beyond the first 3 months after stroke," said Prof. Christopher Chen, neurologist at the National University of Singapore and the principal investigator of the CHIMES study. "The CHIMES-E study provides new insight on the need for long-term assessment of post-stroke recovery in clinical trials of agents with neuroprotective and neurestorative properties such as NeuroAiD."
These results confirm the hypothesis raised by the CHIMES investigators: longer treatment duration and follow-up beyond 3 months of stroke patients is needed to assess stroke recovery.
Source:
Moleac

No comments:

Post a Comment